Evidence map›Paper›PMID 19106304›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2009

Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease.

Sander I van Kasteren, Sandra J Campbell, Sébastien Serres, Daniel C Anthony, Nicola R Sibson, Benjamin G Davis

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 242 citations in OpenAlex.

  1. Photolytic disruption of Alzheimer's amyloid AβCommunications chemistry · 2026
    Article
  2. E-selectin in vascular pathophysiology.Frontiers in immunology · 2024
    Review
  3. Review
  4. MRI Contrast Agents in Glycobiology.Molecules (Basel, Switzerland) · 2022
    Review
  5. Glyco-nanotechnology: A biomedical perspective.Nanomedicine : nanotechnology, biology, and medicine · 2022
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Theranostics · 2018
    Review
  18. Article
  19. Article
  20. Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sander I van KasterenDepartment of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford, OX1 3TA, United Kingdom.
Sandra J Campbell
Sébastien Serres
Daniel C Anthony
Nicola R Sibson
Benjamin G Davis
Churchill Hospital · GBUniversity of Oxford · GB

Funding

Biotechnology and Biological Sciences Research Council BB/E004350/1Biotechnology and Biological Sciences Research Council EGA17763Cancer Research UK C28462/A10158Medical Research Council G0400131Medical Research Council G0401438Medical Research Council G0500853
6 · The paper itself

Abstract

Initial recruitment of leukocytes in inflammation associated with diseases such as multiple sclerosis (MS), ischemic stroke, and HIV-related dementia, takes place across intact, but activated brain endothelium. It is therefore undetectable to symptom-based diagnoses and cannot be observed by conventional imaging techniques, which rely on increased permeability of the blood-brain barrier (BBB) in later stages of disease. Specific visualization of the early-activated cerebral endothelium would provide a powerful tool for the presymptomatic diagnosis of brain disease and evaluation of new therapies. Here, we present the design, construction and in vivo application of carbohydrate-functionalized nanoparticles that allow direct detection of endothelial markers E-/P-selectin (CD62E/CD62P) in acute inflammation. These first examples of MRI-visible glyconanoparticles display multiple copies of the natural complex glycan ligand of selectins. Their resulting sensitivity and binding selectivity has allowed acute detection of disease in mammals with beneficial implications for treatment of an expanding patient population suffering from neurological disease.

Indexed as

NanoparticlesPolysaccharidesAnimalsBiomarkersBrainBrain DiseasesEndothelium, VascularE-SelectinInflammationMagnetic Resonance ImagingMaleP-SelectinRatsRats, WistarBiomarkersE-SelectinPolysaccharidesP-Selectin

Identifiers

PMID19106304
PMCPMC2607245
OpenAlexW2098794307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.